At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 12, 2026 at 18:30 ET
Eisai and Biogen launched LEQEMBI Pen, the subcutaneous autoinjector formulation of lecanemab, in Japan following NHI Drug Price listing. This is the second country launch after the U.S., offering once-weekly self-administration to reduce clinic visit burden and healthcare resource use for Alzheimer's disease patients.
- LEQEMBI Pen launched in Japan on Nov 12, 2026, after NHI Drug Price listing at 27,141 JPY per pen.
- Japan is the second country after the U.S. to launch the subcutaneous formulation.
- LEQEMBI Pen is an autoinjector for once-weekly self-administration (500 mg total via two pens).
- SC formulation showed similar exposure to IV and lower injection-related reaction incidence (1.4% vs IV).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access